Major New Study Provides Important Insights for Effective Treatment of Heart Failure with Preserved Ejection Fraction

Analysis of more than 5 million hospitalizations for heart failure uncovered important insights, according to a new report in The American Journal of Medicine

Philadelphia, PA, July 26, 2016

Heart failure with preserved ejection fraction (HFpEF) has been particularly difficult to treat, or even describe, with definitions and terminology still under debate within the medical community. The number of patients hospitalized with HFpEF is now comparable to those with traditional heart failure with a reduced ejection fraction (HFrEF) and is projected to exceed that of HFrEF within the next few years. Therefore, it has become even more important to characterize the typical HFpEF patient and uncover factors that influence poor outcomes. In a new report published in The American Journal of Medicine, researchers analyzed over five million hospitalizations for acute heart failure, which provided much needed insights.

“There is a need for studies that analyze HFpEF on a national scale, capable of reporting on the population’s inherent heterogeneity using a broadly inclusive cohort, as such studies offer the promise of filling the gaps of knowledge that remain in the understanding of HFpEF, a disease process that still lacks proven therapies,” explained lead investigator Parag Goyal, MD, an advanced heart failure fellow in the Division of Cardiology in the Weill Department of Medicine at Weill Cornell Medicine and at NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY.

This study, conducted by researchers at Weill Cornell Medicine and NewYork-Presbyterian, represents the largest group to date of patients hospitalized with HFpEF. HFpEF is characterized by a “stiff ventricle” and patients typically have other medical conditions including hypertension, diabetes, lung disease, and/or chronic renal failure. Data were obtained from the Nationwide Inpatient Sample of all nonfederal U.S. hospitals through the Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project for over five million hospitalized patients aged 18 and older from 2003-2012. Of the 5,046,879 hospitalizations for acute heart failure, 46% (2,329,391) of patients were diagnosed with HFpEF and 54% (2,717,488) had HFrEF. Patient and hospital characteristics, in-hospital mortality, and length of stay were examined.

There are several important findings in this nationally representative sample of U.S. hospital discharges examining HFpEF:

  1. HFpEF is, in fact, common among patients hospitalized with acute heart failure.
  2. Patients with HFpEF were most often women and elderly (75 years of age or older) who suffered from several other medical conditions.
  3. Over time, in-hospital mortality rates and length of stay for HFpEF improved in a subset of patients.
  4. Pulmonary hypertension was the strongest correlate for in-hospital mortality.
  5. Patients with other, treatable, disorders had a greater likelihood of in-hospital survival.

These data also revealed that HFpEF is potentially more severe in men, since men experienced higher rates of in-hospital mortality compared with women, and did not experience the decreases of in-hospital mortality that women experienced. Among individuals with HFpEF, blacks had lower in-hospital mortality rates compared with whites, a finding that may be related to the fact that blacks with HFpEF present at younger ages. “Whether these key differences stem from disproportionately inadequate treatment of hypertension in blacks or racial differences in left ventricular adaptive mechanisms warrants further investigation,” commented Dr. Goyal.

Dr. Goyal and his colleagues stress that there remains an ongoing need to develop effective treatment strategies for this growing population.


Notes for editors
The article is "Characteristics of Hospitalizations for Heart Failure with Preserved Ejection Fraction," by Parag Goyal, MD, Zaid I. Almarzooq, MD, Evelyn M. Horn, MD, Maria G. Karas, MD, Irina Sobol, MD, Rajesh V. Swaminathan, MD, Dmitriy N. Feldman, MD, Robert M. Minutello, MD, Harsimran S. Singh, MD, Geoffrey W. Bergman, MD, S. Chiu Wong, MD, and Luke K. Kim, MD (doi: 10.1016/j.amjmed.2016.02.007). It appears in The American Journal of Medicine, volume 129, issue 6 (2016), published by Elsevier.

A video discussing the article is available at Full text of this article is available to credentialed journalists upon request. Contact Jane Grochowski at +1 215 239 3712 or to obtain copies. Journalists who would like to interview the authors should contact Parag Goyal at

About The American Journal of Medicine
The American Journal of Medicine, known as the “Green Journal,” is one of the oldest and most prestigious general internal medicine journals published in the United States. It has an Impact Factor of 5.61 and is ranked #13 out of 151 General and Internal Medicine titles based on number of total citations, according to the 2015 Journal Citation Reports® published by Thomson Reuters.

AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus US medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

Media contactJane Grochowski
Publisher, Elsevier
+1 215 239 3712